Notwithstanding promising click here clinical data, copyright's Vyndamax, a medication for hereditary transthyretin-mediated amyloidosis (hATTR), is facing significant opposition from managed care entities. Such organizations are typically creating limitations to access, such as steep expense restrictions and prior authorization that restrict user